Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older

Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older

High-dose therapy (HDT) for non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) is considered a feasible option for patients aged 60 years. This study compared the outcomes for all patients aged 60 years treated with HDT at the center to a matched cohort group aged

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia & lymphoma 2005-11, Vol.46 (11), p.1575-1579
Hauptverfasser: Mileshkin, L. R., Seymour, J. F., Wolf, M. M., Gates, P., Januszewicz, E. H., Joyce, P., Prince, H. M.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Age Factors
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cardiovascular Diseases - chemically induced
Case-Control Studies
Drug-Related Side Effects and Adverse Reactions
Elderly
Female
high-dose therapy
Humans
Lymphoma, Non-Hodgkin - complications
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - mortality
Male
Middle Aged
multiple myeloma
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
non-Hodgkins lymphoma
Peripheral Blood Stem Cell Transplantation - adverse effects
Prognosis
Retrospective Studies
Survival Analysis
transplantation
Transplantation, Autologous
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:High-dose therapy (HDT) for non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) is considered a feasible option for patients aged 60 years. This study compared the outcomes for all patients aged 60 years treated with HDT at the center to a matched cohort group aged
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190500235884